Drug Profile
Research programme: Alzheimer's disease therapies - Andrx
Alternative Names: Alzheimer's disease therapies research programme - AndrxLatest Information Update: 28 Sep 2006
Price :
$50
*
At a glance
- Originator Andrx Corporation
- Class
- Mechanism of Action HMG-CoA reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Alzheimer's disease
Most Recent Events
- 28 Sep 2006 Discontinued - Preclinical for Alzheimer's disease in USA (unspecified route)
- 28 Mar 2001 Preclinical development for Alzheimer's disease in USA (Unknown route)